Galmed Announces the Breakthrough Development of Novel LNP Cardiac Targeted Formulation of its SCD1 inhibitor, Aramchol

AramcholPositive

AI Analysis

Summary

Galmed announced development of a novel lipid nanoparticle formulation of its SCD1 inhibitor Aramchol in collaboration with Barcode Nanotech, designed to target heart tissue and treat cardiac fibrosis.

Importance:5/10

Sentiment:

0.60

drug developmentformulationLNPcardiaccollaborationSCD1 inhibitor

Related Companies

$GLMD

Read the original article

Published by PR Newswire Biotech on July 16, 2026 11:30 AM

Read Original